Tuparstobart

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name

Tuparstobart

DrugBank Accession Number

DB19118

Background

Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS ≥ 1) Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck).

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Protein Chemical Formula

Not Available

Protein Average Weight

Not Available

Sequences

Not Available

Synonyms

Anti-LAG-3 Monoclonal Antibody INCAGN02385
gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV1-46*02 (80.4%)-(IGHD) -IGHJ4*01 (100%), CDR-IMGT[8.8.14] (26-33.51-58.97-110)) (1-121)-Homo sapiens IGHG1*03, G1m3, nG1m1, G1v29 CH2 A84.4 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 N8
Immunoglobulin G1 [301-alanine,de-C-terminal-lysine], anti-(human lymphocyte activation gene-3 protein) (human-Mus musculus monoclonal INCAGN02385 γ1-chain), disulfide with human-Mus musculus monoclonal INCAGN02385 κ-chain, dimer
immunoglobulin G1-kappa,anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody

External IDs

AGEN-2385
AGEN2385
INCAGN-02385
INCAGN02385

Unlock the secrets to drugging the undruggable

Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.

Download eBook

Unlock the secrets to drugging the undruggable

Download eBook

Pharmacology

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Chemical Identifiers

UNII: Z0A08C63DF
CAS number: 2649466-03-3

References

General References: Not Available
External Links: Not Available

Clinical Trials

Clinical Trials Clinical Trial & Rare Diseases Add-on Data Package Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
2	Recruiting	Treatment	Clinical Stage IV Merkel Cell Carcinoma AJCC v8 / Merkel Cell Carcinoma / Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8	1	somestatus	stop reason	just information to hide
2	Recruiting	Treatment	Endometrial Cancer	1	somestatus	stop reason	just information to hide
2	Recruiting	Treatment	Head And Neck Cancer	1	somestatus	stop reason	just information to hide
2	Terminated	Treatment	Urothelial Carcinoma	1	somestatus	stop reason	just information to hide
1	Completed	Treatment	Cervical Cancer / Diffuse Large B-Cell Lymphoma (DLBCL) / Esophageal Cancer / Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]) / Hepatocellular Carcinoma / Melanoma Excluding Uveal Melanoma / Merkel Cell Carcinoma / Mesothelioma / Microsatellite Instability (MSI)-High Endometrial Cancer / Microsatellite Instability High Colorectal Cancer / Non-Small Cell Lung Cancer (NSCLC) / Ovarian Cancer / Renal Cell Carcinoma (RCC) / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Triple-Negative Breast Cancer / Urothelial Carcinoma	1	somestatus	stop reason	just information to hide

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Drug created at July 04, 2024 16:03 / Updated at July 05, 2024 04:35

Tuparstobart

Identification

Pharmacology

Interactions

Categories

Chemical Identifiers

References

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Pharmacoeconomics

Properties